DE69510696T2 - 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen - Google Patents

2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen

Info

Publication number
DE69510696T2
DE69510696T2 DE69510696T DE69510696T DE69510696T2 DE 69510696 T2 DE69510696 T2 DE 69510696T2 DE 69510696 T DE69510696 T DE 69510696T DE 69510696 T DE69510696 T DE 69510696T DE 69510696 T2 DE69510696 T2 DE 69510696T2
Authority
DE
Germany
Prior art keywords
benzopyran
methoxyphenyl
oxo
amino
proliferative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69510696T
Other languages
English (en)
Other versions
DE69510696D1 (de
Inventor
Alexander BRIDGES
Alan SALTIEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE69510696D1 publication Critical patent/DE69510696D1/de
Publication of DE69510696T2 publication Critical patent/DE69510696T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
DE69510696T 1995-01-24 1995-11-27 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen Expired - Fee Related DE69510696T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/378,131 US5525625A (en) 1995-01-24 1995-01-24 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
PCT/US1995/015373 WO1996022985A1 (en) 1995-01-24 1995-11-27 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-[1]benzopyran for treating proliferative disorders

Publications (2)

Publication Number Publication Date
DE69510696D1 DE69510696D1 (de) 1999-08-12
DE69510696T2 true DE69510696T2 (de) 1999-12-23

Family

ID=23491857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69510696T Expired - Fee Related DE69510696T2 (de) 1995-01-24 1995-11-27 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen

Country Status (12)

Country Link
US (1) US5525625A (de)
EP (1) EP0805807B1 (de)
JP (1) JPH10512878A (de)
AT (1) ATE181913T1 (de)
CA (1) CA2208075A1 (de)
DE (1) DE69510696T2 (de)
DK (1) DK0805807T3 (de)
ES (1) ES2137554T3 (de)
GR (1) GR3031295T3 (de)
NZ (1) NZ297320A (de)
WO (1) WO1996022985A1 (de)
ZA (1) ZA96528B (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
CA2281903A1 (en) 1997-03-28 1998-10-08 The Research Foundation Of State University Of New York Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
DE69836378T2 (de) * 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
WO1999034792A1 (en) * 1998-01-06 1999-07-15 The General Hospital Corporation Use of mek1 inhibitors as protective agents against damage due to ischemia
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
ES2268854T3 (es) * 1998-03-24 2007-03-16 Chugai Seiyaku Kabushiki Kaisha Inhibidores de la vascularizacion.
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
AU1127700A (en) * 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
EP1140046A1 (de) * 1998-12-15 2001-10-10 Warner-Lambert Company Verwendung von einem mek hemmer zur vorbeugung von transplantatabstossung
EP1143957A3 (de) * 1998-12-16 2002-02-27 Warner-Lambert Company Mek inhibitoren zur behandlung von arthritis
BR9916785A (pt) * 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
CN1149204C (zh) * 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
WO2000042003A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2348236A1 (en) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2002534497A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
ID30439A (id) 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
WO2000050030A1 (en) * 1999-02-25 2000-08-31 Ted Ebendal New use
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
EP1339702A1 (de) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amid-substituierte diarylamine als mek inhibitoren
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
AU2002249261A1 (en) * 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
US6806293B1 (en) * 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
EP1409656A4 (de) * 2001-03-12 2005-01-12 Darley Pharmaceuticals Ltd Screening von nichtpeptidischen, nichtsteroiden pheromonverbindungen von invertebraten auf eine mitogenaktivierte proteinkinase modulierende aktivität
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
BR0307060A (pt) * 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
CA2475206A1 (en) * 2002-02-15 2003-08-15 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
TW200406203A (en) * 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
JPWO2004075915A1 (ja) * 2003-02-26 2006-06-01 興和株式会社 アレルギー性接触性皮膚炎治療薬
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051301A2 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
RU2006121990A (ru) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
CA2587178A1 (en) * 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
AR055057A1 (es) * 2005-05-18 2007-08-01 Array Biopharma Inc Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria.
WO2007021933A2 (en) * 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2656364C (en) 2006-07-06 2014-11-25 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
ATE523499T1 (de) * 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
US8377937B2 (en) * 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
TWI450720B (zh) 2007-07-05 2014-09-01 Array Biopharma Inc 作為ａｋｔ蛋白質激酶抑制劑之嘧啶環戊烷
AU2008282273A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
ES2401685T3 (es) * 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
AU2009204025B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2560878T3 (es) * 2008-08-04 2016-02-23 Merck Patent Gmbh Compuestos novedosos de fenilamino-isonicotinamida
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
CN103874689B (zh) 2011-04-01 2016-04-27 基因泰克公司 Akt抑制剂化合物和威罗菲尼的组合及使用方法
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
EP2714039A1 (de) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Kombinationstherapie aus hsp90-hemmenden verbindungen und mek-hemmern
WO2012160130A1 (en) 2011-05-25 2012-11-29 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
US20140242595A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
EP3579872A1 (de) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs in verbindung mit aktivierung der mapk-leitungsbahn
WO2020051370A1 (en) * 2018-09-06 2020-03-12 North Carolina Central University Discovery of novel potent inhibitors of the map3k mekk2
US20220288040A1 (en) 2019-09-02 2022-09-15 Inserm (Institut National De La Santé Et De La Recherche Médicale)) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816466A (en) * 1971-12-22 1974-06-11 Warner Lambert Co Flavanoid ring systems
US5116954A (en) * 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
JPH05286962A (ja) * 1992-02-14 1993-11-02 Kyowa Hakko Kogyo Co Ltd ５−アミノフラボン誘導体

Also Published As

Publication number Publication date
DK0805807T3 (da) 2000-01-17
US5525625A (en) 1996-06-11
EP0805807B1 (de) 1999-07-07
WO1996022985A1 (en) 1996-08-01
AU4245696A (en) 1996-08-14
ES2137554T3 (es) 1999-12-16
NZ297320A (en) 1999-05-28
ZA96528B (en) 1996-08-15
MX9704649A (es) 1997-09-30
ATE181913T1 (de) 1999-07-15
CA2208075A1 (en) 1996-08-01
EP0805807A1 (de) 1997-11-12
GR3031295T3 (en) 1999-12-31
AU690400B2 (en) 1998-04-23
JPH10512878A (ja) 1998-12-08
DE69510696D1 (de) 1999-08-12

Similar Documents

Publication Publication Date Title
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
NL300140I2 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
NO994330L (no) Metode for behandling av en tumor
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
ZA9610073B (en) Method of using beta-interferons to treat restenosis
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
DE59908268D1 (de) Khellin-zubereitung und deren verwendung zur topischen therapie
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
UA8280A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee